Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.33 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | GPR3 | P46089 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19760752 | 1.00 | PNMT (0.33) | PNMTCYP1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL29612142 | 1.00 | PNMT (0.33) | PNMTCYP1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL24026964 | 0.88 | CCKBR (0.35) | PNMTCYP1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL29317134 | 0.67 | GPR3 (0.40) | PNMTCYP1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL3062843 | 0.67 | GRIN2D (0.42) | — | |
| SCHEMBL19760715 | 0.66 | GPER1 (0.37) | PNMT | |
| SCHEMBL29611854 | 0.64 | PNMT (0.62) | PNMT | |
| SCHEMBL26837118 | 0.63 | PNMT (0.50) | PNMT | |
| SCHEMBL24026979 | 0.60 | GPER1 (0.38) | PNMT | |
| SCHEMBL30071485 | 0.57 | GPR3 (0.35) | PNMTGPR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3472162-B1 | HETEROARYL ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2021-11-17 | — | — | EP | disclosed |
| US-20180002344-A1 | HETEROARYL ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2018-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180002344-A1 | HETEROARYL ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, GPER1, ESRRA | PNMT 2793/4885CYP1A1 162/4885CYP1A2 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.